LifeMD Expands Collaboration with Novo Nordisk to Offer Wegovy® Pill
Company Symbol: LFMD | Date: January 5, 2026
Introduction
LifeMD, Inc. (Nasdaq: LFMD), a premier provider of virtual primary care services, has announced a significant expansion in its healthcare offerings. The company is now providing patients with Novo Nordisk’s Wegovy® (semaglutide) pill, the first and only FDA-approved oral GLP-1 therapy designed for chronic weight management and cardiovascular health. This innovative telehealth solution enables eligible patients to access Wegovy® for as little as $149 per month, enhancing LifeMD's commitment to affordable, branded treatment options.
Key Features of Wegovy® Pill
On December 22, 2025, the U.S. Food and Drug Administration (FDA) granted approval for Wegovy® as the sole oral GLP-1 therapy on the market. This therapy aims to reduce excess body weight, assist in sustained weight maintenance, and lower the risk of major cardiovascular events. Key highlights include:
- Weight Loss Efficacy: Clinical trials demonstrated an impressive 16.6% mean weight loss with Wegovy® compared to just 2.7% with placebo, over a 64-week period.
- Accessible Treatment: The oral formulation allows for broader patient access, catering especially to those hesitant about weekly injections.
Strengthening Collaboration With Novo Nordisk
This announcement marks a new chapter in LifeMD’s long-standing partnership with Novo Nordisk. LifeMD is now prominently featured on both the NovoCare® and Wegovy® websites as a trusted telehealth provider, underscoring a growing demand for clinically supported GLP-1 therapies.
Justin Schreiber, Chairman and CEO of LifeMD, stated, “In close collaboration with Novo Nordisk, we moved quickly to bring the Wegovy® pill to patients at an attractive cash-pay price, reinforcing our role as a preferred virtual destination for evidence-based medical weight management.”
Comprehensive Care and Accessibility
LifeMD’s integration with NovoCare® Pharmacy ensures streamlined access to both Wegovy® and other FDA-approved GLP-1 medications like Ozempic®. The comprehensive service package includes:
- Virtual consultations with licensed healthcare providers across all 50 states
- Ongoing clinical support and nationwide diagnostic testing
- Fast prescription fulfillment with tracking, and simplified billing
As Dave Moore, Executive Vice President of U.S. Operations at Novo Nordisk, noted, “Our collaboration with LifeMD provides a trusted telehealth option for patients seeking authentic, FDA-approved treatment options.”
Cost and Availability of Wegovy®
The Wegovy® pill is available to LifeMD patients who are uninsured or lack insurance coverage for weight-loss medications. Current pricing is as follows:
- Wegovy® 1.5mg and 4mg: $149 per month
- From April 15, 2026, Wegovy® 4mg will be priced at $199 per month
- 9mg and 25mg doses will be available at $299 per month
About LifeMD, Inc.
LifeMD is a leading provider of virtual primary care services, offering telemedicine and access to laboratory and pharmacy services for over 200 health conditions. The company utilizes a vertically integrated digital care platform alongside a U.S.-based patient care center to enhance access to affordable, quality healthcare.
For more details, visit LifeMD.com.